Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, Tampa, Florida; Medical Imaging Centre, Semmelweis University, Budapest, Hungary.
Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, Tampa, Florida.
J Vasc Interv Radiol. 2022 Sep;33(9):1061-1065. doi: 10.1016/j.jvir.2022.05.023.
Transarterial radioembolization (TARE) with yttrium-90 glass microspheres is widely used to treat primary and secondary malignancies in the liver. However, the safety and efficacy of TARE in patients with liver-dominant metastatic castration-resistant prostate cancer (mCRPC) is unknown. A proof-of-concept, retrospective analysis of 7 consecutive patients with liver-dominant mCRPC who were treated with TARE was performed. The median overall survival was 27.2, 32.1, and 108.1 months from the time of TARE, the diagnosis of liver metastases, and initial cancer diagnosis, respectively. The median liver progression-free survival was 7.3 months. No grade 3 or higher adverse effects were noted. TARE was found to be a safe and effective tool for treating patients with liver-dominant mCRPC in this limited cohort.
经动脉放射性栓塞术（TARE）联合钇-90 玻璃微球被广泛用于治疗肝脏原发性和继发性恶性肿瘤。然而，对于肝脏转移去势抵抗性前列腺癌（mCRPC）患者，TARE 的安全性和有效性尚不清楚。本研究回顾性分析了 7 例接受 TARE 治疗的肝脏转移去势抵抗性前列腺癌患者，这是一项概念验证研究。从 TARE 治疗时间、肝转移诊断时间和初始癌症诊断时间开始，患者的中位总生存期分别为 27.2、32.1 和 108.1 个月。中位肝脏无进展生存期为 7.3 个月。未观察到 3 级或更高级别的不良反应。在这个有限的队列中，TARE 被发现是治疗肝脏转移去势抵抗性前列腺癌患者的一种安全有效的工具。
